Previous 10 | Next 10 |
home / stock / bpmuf / bpmuf news
Basel/Allschwil, Switzerland, April 26, 2023 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, reported that shareholders approved all proposals of the board of directors...
Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, April 18, 2023 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, provided an updated time...
– Milestone related to the launch of Cresemba in Japan Basel/Allschwil, Switzerland, March 23, 2023 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fun...
Basilea Pharmaceutica AG, Inc. (BPMUF) Q4 2022 Earnings Conference Call February 14, 2023, 10:00 ET Company Participants David Veitch - CEO Adesh Kaul - CFO Marc Engelhardt - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Fitzgerald...
Basilea Pharmaceutica AG press release ( OTC:BPMUF ): FY GAAP EPS of CHF 1.02. Revenue of CHF 147.8M (-0.2% Y/Y). In 2022, a positive net cash flow of CHF 7.1M was provided by operating activities. Cash and cash equivalents, restricted cash and short-term i...
22% year-on-year increase of royalty income from antifungal Cresemba ® Operating profit of CHF 18.5 million and net profit of CHF 12.1 million Strengthened balance sheet through non-dilutive repayment of convertible bonds Expecting approximately 20% growth in ...
Basel/Allschwil, Switzerland, February 07, 2023 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the ant...
Basilea Pharmaceutica ( OTC:BPMUF ) expects an operating profit of about CHF18M and also anticipates net profit, for the financial year 2022 as per preliminary results. The Swiss company had previously guided for an operating loss of CHF10M to CHF15M for 2022. "Our stro...
Successful implementation of strategic decision to focus on anti-infectives and stronger than expected revenue lead to profitability earlier than anticipated Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, January 24, 2023 Basilea Pharmaceutica Ltd...
Basilea Pharmaceutica ( OTC:BPMUF ) said Wednesday revenue contributions from Cresemba and Zevtera are expected to amount to about CHF 122 million for fiscal 2022. Total revenue, which includes BARDA reimbursements, proceeds from oncology transactions and other revenue in addition to ...
News, Short Squeeze, Breakout and More Instantly...
Basilea Pharm Ag Akt Shs Company Name:
BPMUF Stock Symbol:
OTCMKTS Market:
China Yuchai International Limited (CYD) is expected to report for Q1 2024 Avid Bioservices Inc. (CDMO) is expected to report $0.03 for Q4 2024 Derwent London Plc (DWVYF) is expected to report for Q1 2024 Fresnillo Plc (FNLPF) is expected to report for Q1 2024 Basilea Pharmaceutic...
GreenTree Hospitality Group Ltd. American depositary shares each representing one Class A (GHG) is expected to report for Q1 2024 Air T Inc. (AIRT) is expected to report for Q4 2024 Alimentation-Couche Tard Inc. - Class A (Multiple Voting) (ANCTF) is expected to report for Q4 2024 Man...
Allschwil, Switzerland, June 20, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement w...